What is MicroBiotiX?
MicroBiotiX is a pioneering biotechnology firm dedicated to the creation of bacteriophage and microbiome-based therapeutics. The company's core focus lies in addressing critical health challenges, including multidrug-resistant bacterial infections and autoimmune diseases. With a robust bacteriophage library cultivated over 15 years, MicrobiotiX targets formidable pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae. Their commitment to quality is further demonstrated by their high-standard GMP facility, ensuring regulatory compliance and product excellence. The company aims to serve healthcare providers and patients grappling with severe resistant infections and other complex medical conditions.
How much funding has MicroBiotiX raised?
MicroBiotiX has raised a total of $14.3M across 1 funding round:
Series B
$14.3M
Series B (2025): $14.3M, investors not publicly disclosed
What's next for MicroBiotiX?
The recent major strategic investment signals a pivotal moment for MicroBiotiX, likely enabling the acceleration of its product development pipeline and the scaling of its GMP manufacturing capabilities. This substantial backing from enterprise-level investors suggests confidence in the company's long-term vision and its potential to disrupt the treatment landscape for intractable diseases. Future strategic moves may involve expanding clinical trials, forging key partnerships within the healthcare ecosystem, and preparing for broader market penetration of its innovative phage and microbiome therapies.
See full MicroBiotiX company page
